NEW MEMBER SIGN UP
  Display Name
 
  Email Address
 
  Password
 
  Password again
 
  Zip
 
Country
 
   

Close Window

Privacy Statement
BioSpace.com

Biotech and Pharmaceutical
News & Jobs
Search the Site
     
Community Login

What is this?
Biotechnology and Pharmaceutical ChannelMedical Device and Diagnostics ChannelClinical Research Channel Employers
 Post Job | Search Resumes | Login

NEWSLETTERS
Free Newsletters
Archive
My eNewsletters

NEWS
News by Subject
News by Disease
News by Date
PLoS
Search News
Post Your News
JoVE

CAREER NETWORK
Job Seeker Login
Most Recent Jobs
Search Jobs
Post Resume
Career Fairs
Career Resources
For Employers

COMMUNITY
Login
Become a Member
Discussion Forums
FAQ

HOTBEDS
Regional News
US & Canada
  Biotech Bay
  Biotech Beach
  Genetown
  Pharm Country
  BioCapital
  BioMidwest
  Bio NC
  BioForest
  Southern Pharm
  BioCanada East
  US Device
Europe
Asia

BIOTECH WORK PORTAL
Career Definitions
Labor Market Reports
Education & Training
Regions

DIVERSITY

INVESTOR
Market Summary
News
IPOs

PROFILES
Company Profiles

START UPS
Companies
Events

INTELLIGENCE
Research Store

INDUSTRY EVENTS
Biotech Events
Post an Event
RESOURCES
Real Estate
Business Opportunities

  News | News By Subject | News by Disease News By Date | Search News
   

CARBOGEN AMCIS Announces Company Restructure; 40 Positions Across Swiss Operations to be Lost
11/4/2009

BUBENDORF, Switzerland -- CARBOGEN AMCIS announced its intention to restructure its Swiss operations. The early phase services, currently provided by its facilities in canton Aargau, will be consolidated at the Aarau site. The Hunzenschwil site will focus on new technologies, such as micro-reactors, crystallisation and the using the unique assets of the site. In addition, the late phase and high potency (HiPo) service groups, business at the Bubendorf facility, will be expanded, due to increased market demand.

The company presently employs 400 people at its Swiss facilities. The proposed changes would result in the loss of up to 40 positions across the Swiss operations.

The past 18 months has seen some significant changes to the markets CARBOGEN AMCIS serves. While the company has seen a significant increase in the number and rate of progress associated with later phase projects, there has been a substantial decline in the number of early phase projects being generated. “CARBOGEN AMCIS has taken the opportunity to review the business and is making these changes to provide the foundation of a future-oriented business,” said Gaudenz von Capeller, managing director, CARBOGEN AMCIS.

“In the last year, we’ve tried our best to keep all jobs intact,” said von Capeller. “Thus far, due to decisions we’ve made, we’ve been able to weather the economy better than most in our industry. As we make the shift, we will continue to ensure that we meet customer demands and provide the same level of customer service. By making these changes we believe that CARBOGEN AMCIS, continues to be a robust and profitable business and a key part of the Dishman group.”

CARBOGEN AMCIS AG is a leading service provider, offering a portfolio of drug-development and commercialization services to the pharmaceutical and biopharmaceutical industry at all stages of drug development. The integrated services provide innovative chemistry solutions to support timely and safe drug development allowing customers to make the best use of available resources. CARBOGEN AMCIS AG is owned by Dishman Pharmaceuticals and Chemicals Ltd., Ahmedabad, India.

Source: CARBOGEN AMCIS AG, Bubendorf, Switzerland

Marijean Jaggers Standing Partnership 3445 Seminole Trail, Suite 196 Charlottesville, VA 22911 434.973.0645 office/fax 636.485.2920 cell Web site: www.standingpr.com


Read at BioSpace.com

   

ADD TO DEL.ICIO.US    ADD TO DIGG    ADD TO FURL    ADD TO STUMBLEUPON    ADD TO TECHNORATI FAVORITES